Article Text

Download PDFPDF

985 PSGL-1 is a novel inhibitor of tumor cell phagocytosis by macrophages
  1. Lok San Wong and
  2. Andre Veillette
  1. Montreal Clinical Research Institute, Montréal, QC, Canada
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background In recent years, macrophages have emerged as an essential component of the antitumor immune response. Indeed, macrophages are able to ‘phagocytose’, i.e., to ingest and kill tumor cells. The cellular and molecular mechanisms that regulate this process have been increasingly investigated.1 Our group and others have demonstrated the implication of specific ligand-receptor pathways involved in the regulation of phagocytosis.2–4 Building on these findings, we aim at identifying additional regulators of phagocytosis which could constitute novel targets for immunotherapy.

Mice Wild-type (WT) mice were generated in the C57Bl/6J background. Sele, Sell, Selp (triple selectin) KO mice were acquired from The Jackson Laboratory (Bar Harbor, Maine, USA).

Cells Bone marrow-derived macrophages (BMDM) and PSGL-1-deficient target cells were generated as previously described.3

Microscopy-based phagocytosis assay This assay was performed as previously described.3 Briefly, BMDMs were coincubated with fluorescently labelled target cells at a ratio of 1:4 (macrophages: target cells). After 2 hours, the cells were washed and imaged with an inverted microscope (Carl Zeiss Axiovert S100 TV). The percentage of phagocytosis was calculated as the number of macrophages containing labelled target cells versus the total number of macrophages. All experiments were repeated at least three times. Statistical analyses were performed on the initial raw values.

Results We have recently identified a molecule at the surface of tumor cells of lymphoid and myeloid lineages, named PSGL-1 (P-selectin glycoprotein ligand 1), that prevents the elimination of these cancer cells by macrophages. PSGL-1 has primarily been described as a ligand for the selectin family of adhesion proteins5 Our results demonstrate that PSGL-1 expression at the surface of tumor cells inhibits phagocytosis and efficient elimination of these cells by macrophages. Indeed, a deficiency in PSGL-1 on these tumor cells increases their phagocytosis (figure 1). Furthermore, we found that this inhibitory effect was independent of selectins, as macrophages lacking all three selectins (Triple Selectin KO) showed no defect in phagocytosis (figure 2).

Conclusions Our results demonstrate a previously unsuspected role of PSGL-1. We observed that loss of PSGL-1 on murine tumor cells (L1210) and human multiple myeloma (RPMI-8226, OPM-2) promotes phagocytosis of these tumor cells. Results not shown here further suggest a novel mechanism of action for PSGL-1 as an anti-phagocytic ligand which likely interacts with an as of yet unknown receptor. For future work, we aim to provide convincing evidence that this pathway could represent a new target for anti-cancer immunotherapy.


  1. Freeman SA, S Grinstein, Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunol Rev, 2014;262(1):193–215.

  2. Chen J, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature, 2017;544(7651):493–497.

  3. Tang Z, et al. Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. Cell Rep, 2021;37(11):110111.

  4. Barkal AA, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol, 2018;19(1):76–84.

  5. Borsig L. Selectins in cancer immunity. Glycobiology, 2018;28(9):648–655.

Abstract 985 Figure 1

Phagocytosis assay of L1210, OPM-2 and RPMI-8226 tumor cells with WT BMDMs

Abstract 985 Figure 2

Phagocytosis assay of L1210 tumor cells with WT or Triple Selectin KO BMDMs

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.